Pressemelding -
AstraZeneca welcomes new Country President for the Nordics
Effective July 1, Anna-Lena Engwall, Country President Nordics, will take on a new global role, and Emelie Antoni, VP Commercial and Global Franchise Head, will succeed her.
As part of our commitment to strategic leadership development, Anna-Lena Engwall and Emelie Antoni will take on new roles within the company. Emelie will assume the position of Country President Nordics & Sweden, reporting to Stefan Woxström, Senior Vice President for Europe and Canada. Anna-Lena will join the Global CVRM (Cardiovascular, Renal and Metabolism) Leadership team as VP Commercial and Global Franchise Head.
“The Nordic region has witnessed a significant climb in positions in the market, securing numerous successful launches across our business. Anna-Lena Engwall has been at the helm of the Nordics, leading it to achieve strong growth and making a significant impact in Sweden and the Nordics. I am looking forward to seeing Emelie Antoni continue to develop our position even further," says Stefan Woxström, SVP EUCAN.
Emelie Antoni has held various positions of increasing responsibility during her 26 years in AstraZeneca, including successfully leading country organisations. Most recently, she has served as the Country President for the Czech Republic and Slovakia, and prior to that, she held the role of Country Director for Baltics & Iceland. In her current role as VP Commercial and Global Franchise Head within the Global CVRM organisation, she has developed successful global brand strategies and led launches in 15 markets.
"It is truly exciting to return to Sweden to lead the Nordic organisation. I am committed to driving further growth and success in the Nordic region together with this high performing and talented organisation, in order to deliver lifesaving medicines to patients," says Emelie Antoni.
With these new roles, Anna-Lena Engwall will be based in the United Kingdom, and Emelie Antoni will return to Sweden to AstraZeneca's headquarters for the Nordic Marketing Company in LifeCity, Stockholm.
Om AstraZeneca
AstraZeneca er et globalt, innovasjonsdrevet biofarmasøytisk selskap med fokus på forskning, utvikling og markedsføring av reseptbelagte legemidler, hovedsakelig for behandling av sykdommer innen tre terapeutiske områder: kreft, kardiovaskulære sykdommer, nyresykdommer og metabolske sykdommer og luftveissykdommer. AstraZeneca opererer i over 100 land og dets innovative medisiner brukes av millioner av pasienter over hele verden. Få flere oplysninger på www.astrazeneca.no og www.astrazeneca.com.
